受体相互作用蛋白激酶1 (RIPK1) 通过NF-κB-TNF-α通路调节子宫癌细胞:一个体外研究
Wenqi Bai1, Fengjie Cui1, Zihan Wang2
1Departments of Oncology Gynecology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu 233004, China.
Translational oncology
|July 29, 2023
概括
受体相互作用蛋白激酶1 (RIPK1) 在宫癌 (CC) 中被上调,促进瘤生长和扩散. 抑制RIPK1可能为CC患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞死亡信号传递
背景情况:
- 宫癌 (CC) 给全球健康带来了重大挑战.
- 受体相互作用蛋白激酶 (RIPK) 家族成员调节炎症和细胞死亡等关键细胞过程.
- 在CC病变发生过程中,RIPK1的特定作用在很大程度上仍未被定义.
研究的目的:
- 研究RIPK1在宫癌中的临床意义和生物功能.
- 探索RIPK1作为CC治疗的潜在治疗点.
主要方法:
- 使用免疫组织化学分析50个CC患者组织中的RIPK1表达.
- 试验室研究包括西部涂抹,CCK-8,殖民地形成和伤口愈合试验.
- 研究RIPK1在NF-κB和TNF信号通路中的调节作用.
主要成果:
- 与相邻组织相比,CC瘤组织中的RIPK1表达显著升高.
- 较高的RIPK1水平与CC患者的预后较差相关.
- 沉默RIPK1抑制了CC细胞的增殖,迁移和入侵在体外.
- 发现RIPK1通过调节NF-κB和TNF来增强CC细胞迁移,入侵和增殖.
结论:
- RIPK1在CC发育和进展中发挥着至关重要的作用,通过促进细胞增殖和扩散,同时抑制细胞亡.
- NF-κB的RIPK1激活和TNF的调节是驱动CC的关键机制.
- RIPK1代表了用于新型宫癌治疗的有希望的分子标.
相关概念视频
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K


